Why an investor's Botox play should raise eyebrows

Investor William Ackman's sneaky bid for Botox maker Allergan went completely under Wall Street's radar. The move is ripe for SEC scrutiny.

There was no sight of any frown lines on the forehead of activist investor William Ackman over the past two months as he quietly bought up almost 10 per cent of specialty healthcare company Allergan. 

The 48-year-old hedge fund manager is clearly trying to keep it that way as he partnered up with Valeant Pharmaceuticals this week to launch an audacious $US46 billion hostile bid for the maker of Botox.



{{ twilioFailed ? 'SMS Code Failed to Send…' : 'An SMS verification code has been sent ...' }}

Hi {{ user.FirstName }}

Looks like you have already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to complete your SMS verification

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device

Verify your mobile number to proceed...

Please check your mobile number below and press the Send Verification Code button. This will be used to complete your verification in the next step.

Please sign up for full access


Updating information

Please wait ...


{{ productPrice }} / day
( GST included )
Price $0
GST $0
Discount -{{productDiscount}}
TOTAL {{productPrice}}
  • Mastercard
  • Visa

Please click on the ACTIVATE button to finalise your membership


The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device

Register as a new member

(using a different email)

Related Articles